Johnson & Johnson (NYSE:JNJ) Trading Down 2.5% – Here’s What Happened

Shares of Johnson & Johnson (NYSE:JNJ) were down 2.5% during trading on Thursday . The stock traded as low as $227.60 and last traded at $228.3670. Approximately 18,876,396 shares traded hands during mid-day trading, an increase of 125% from the average daily volume of 8,393,819 shares. The stock had previously closed at $234.20.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on JNJ. Guggenheim increased their price target on Johnson & Johnson from $244.00 to $266.00 and gave the stock a “buy” rating in a research note on Monday, April 20th. Royal Bank Of Canada reissued an “outperform” rating and set a $265.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 15th. Bank of America raised their price target on shares of Johnson & Johnson from $253.00 to $254.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research report on Wednesday, April 15th. Finally, Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective for the company in a research note on Wednesday, May 13th. Twenty research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $253.04.

Johnson & Johnson Stock Down 2.5%

The firm has a market capitalization of $549.73 billion, a PE ratio of 26.40, a P/E/G ratio of 2.30 and a beta of 0.26. The company has a 50-day moving average price of $231.07 and a 200 day moving average price of $227.93. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were given a dividend of $1.34 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend was Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.3%. Johnson & Johnson’s payout ratio is 61.97%.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Johnson & Johnson

A number of institutional investors have recently modified their holdings of JNJ. Blueline Advisors LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth $25,000. Cresta Advisors Ltd. purchased a new position in Johnson & Johnson during the fourth quarter valued at $26,000. DecisionPoint Financial LLC grew its position in shares of Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after purchasing an additional 75 shares during the period. Bay Harbor Wealth Management LLC raised its position in shares of Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after purchasing an additional 49 shares during the last quarter. Finally, Family CFO Inc purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.